THAR - NASDAQ

Tharimmune, Inc.

THAR·NASDAQ

$3.38

+0.86%

HealthcareBiotechnology

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$133.41M

EPS-1.1200

P/E Ratio-3.14

Earnings Date06/03/2026

519.15M

Assets

13849%

3Y+7662.0%

5Y+176002.0%

10Y+1269797.0%

121.22M

Total Liabilities

4922%

3Y+10487.0%

5Y+2921.0%

10Y+7189.0%

397.93M

Total Equity

30331%

3Y+7078.0%

5Y-10804.0%

10Y-24630.0%

Tharimmune, Inc. Funding & Solvency Profile

THAR · NASDAQ

Current Assets

Cash & Cash Equivalents17.03M

Net Receivables0.00

Inventory0.00

Other Current Assets353.32K

Total Current Assets17 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets501.76M

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets0

Total Assets

519.15M

Financial Health Analysis

Current Ratio

5.29x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.30x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

14 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

3% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Tharimmune, Inc. Balance Sheet

THAR • NASDAQ

Tharimmune, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	17M	3.6M	10.9M	6.5M	4.4K	191.9K	38.3K
Cash & Short-Term Investments	17M	3.6M	10.9M	6.5M	4.4K	191.9K	38.3K
Prepaids	0.0	0.0	0.0	0.0	70.7K	102.9K	2.6K
Other Current Assets	353.3K	162.3K	11K	178.1K	546.7K	0.0	0.0
Total Current Assets	17.4M	3.7M	10.9M	6.7M	621.7K	294.8K	40.9K
NON-CURRENT ASSETS
Intangible Assets	501.8M	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	501.8M	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Assets	501.8M	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	519.1M	3.7M	10.9M	6.7M	621.7K	294.8K	40.9K
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.1M	1.1M	908.6K	954.5K	1.7M	714.8K	496.5K
Accounts Payable	1.1M	1.1M	908.6K	954.5K	1.5M	514.8K	241.4K
Other Payables	0.0	0.0	0.0	0.0	200K	200K	255.1K
Accrued Expenses	2.2M	0.0	906.5K	190.5K	497.8K	121.8K	77.1K
Short Term Debt	0.0	0.0	0.0	0.0	1.4M	563.4K	430.6K
Other Current Liabilities	0.0	1.3M	0.0	0.0	980.2K	1.3M	126.2K
Total Current Liabilities	3.3M	2.4M	1.8M	1.1M	4.5M	2.7M	1.1M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	772.9K	1.3M	532.8K
Deferred Tax Liabilities (Non-Current)	117.9M	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	117.9M	0.0	0.0	0.0	772.9K	1.3M	532.8K
Total Liabilities	121.2M	2.4M	1.8M	1.1M	5.3M	4M	1.7M
SHAREHOLDERS' EQUITY
Treasury Stock	-70K	-70K	-70K	-70K	0.0	0.0	0.0
Common Stock	3.7K	198.0	1.2K	46.0	636.0	636.0	628.0
Additional Paid-In Capital	470.8M	38.3M	33.9M	21M	2.2M	986.4K	462.7K
Retained Earnings	-72.8M	-36.9M	-24.7M	-15.4M	-6.9M	-4.7M	-2.1M
Total Stockholders' Equity	397.9M	1.3M	9.1M	5.5M	-4.7M	-3.7M	-1.6M
Total Equity	397.9M	1.3M	9.1M	5.5M	-4.7M	-3.7M	-1.6M
SUMMARY
Total Liabilities & Equity	519.1M	3.7M	10.9M	6.7M	621.7K	294.8K	40.9K
Total Debt	0.0	0.0	0.0	0.0	2.2M	1.9M	963.4K
Net Debt	-17M	-3.6M	-10.9M	-6.5M	2.2M	1.7M	925.1K
Shares Outstanding	35,044,810	35,044,810	35,044,810	35,044,810	35,044,810	35,044,810	35,044,810

SEC Filings

THAR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-K 10-K 2025 FY FY	March 31, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 18, 2026	February 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 06, 2026	February 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 02, 2026	January 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 26, 2026	January 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 22, 2026	January 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 20, 2026	January 20, 2026	2026	View Filing

Showing 1 to 10 of 113 filings

Related Guides

Blog Categories

Continue your THAR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.